Cumberland Pharmaceuticals Inc
CPIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001087294
No open-market purchases or sales by Cumberland Pharmaceuticals Inc insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $16.0M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Cumberland Pharmaceuticals Inc as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −4 vs. Q1 2022
- Shares held
- 2.71M
- −190.1K (−6.6%) vs. Q1 2022
- Total value
- $5.62M
- −$2.55M (−31.2%) vs. Q1 2022
- New holders
- 1
- 7 more added
- Sold out
- 5
- 10 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CPIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 32 | $16.0M |
| Q1 2026 | 29 | $8.97M |
| Q4 2025 | 27 | $11.8M |
| Q3 2025 | 30 | $10.6M |
| Q2 2025 | 31 | $12.3M |
| Q1 2025 | 33 | $18.1M |
| Q4 2024 | 20 | $4.36M |
| Q3 2024 | 22 | $2.61M |
| Q2 2024 | 23 | $3.18M |
| Q1 2024 | 23 | $3.63M |
| Q4 2023 | 25 | $3.89M |
| Q3 2023 | 21 | $4.17M |
| Q2 2023 | 23 | $3.52M |
| Q1 2023 | 21 | $4.77M |
| Q4 2022 | 23 | $5.61M |
| Q3 2022 | 17 | $5.89M |
| Q2 2022 | 22 | $5.62M |
| Q1 2022 | 26 | $8.17M |
| Q4 2021 | 26 | $13.2M |
| Q3 2021 | 23 | $7.43M |
| Q2 2021 | 28 | $8.36M |
| Q1 2021 | 31 | $9.77M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Cumberland Pharmaceuticals Inc; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dimensional Fund Advisors LP | 627,200 | $1.30M | 0.00% | −6,704−1.1% | Reduced |
| Renaissance Technologies LLC | 622,228 | $1.29M | 0.00% | −22,535−3.5% | Reduced |
| Vanguard Group Inc | 374,691 | $778.0K | 0.00% | −3,293−0.9% | Reduced |
| Bridgeway Capital Management, LLC | 286,655 | $595.0K | 0.01% | 00.0% | Unchanged |
| Berkshire Asset Management LLC | 189,048 | $392.0K | 0.03% | +6,907+3.8% | Added |
| Acadian Asset Management LLC | 188,164 | $390.0K | 0.00% | −790.0% | Reduced |
| BlackRock Inc. | 140,248 | $292.0K | 0.00% | +1,346+1.0% | Added |
| Geode Capital Management, LLC | 74,718 | $155.0K | 0.00% | +2,482+3.4% | Added |
| Two Sigma Investments, LP | 51,502 | $107.0K | 0.00% | −37,581−42.2% | Reduced |
| State Street Corp | 43,045 | $89.0K | 0.00% | +1,000+2.4% | Added |
| Two Sigma Advisers, LP | 34,592 | $72.0K | 0.00% | −69,226−66.7% | Reduced |
| Sterling Financial Planning, Inc. | 22,031 | $46.0K | 0.03% | 00.0% | Unchanged |
| Northern Trust Corp | 18,344 | $38.0K | 0.00% | −2,273−11.0% | Reduced |
| Millennium Management LLC | 10,835 | $22.0K | 0.00% | −3,372−23.7% | Reduced |
| Prudential Financial Inc | 10,300 | $21.0K | 0.00% | +10,300 | New |
| Tower Research Capital LLC (TRC) | 4,898 | $10.0K | 0.00% | +2,013+69.8% | Added |
| UBS Group AG | 3,783 | $8.00K | 0.00% | +503+15.3% | Added |
| Morgan Stanley | 2,660 | $6.00K | 0.00% | −495−15.7% | Reduced |
| Oakworth Capital, Inc. | 3,052 | $6.00K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 579 | $1.00K | 0.00% | +475+456.7% | Added |
| Wells Fargo & Company | 57 | $0 | 0.00% | −1,695−96.7% | Reduced |
| Huntington National Bank | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −19,843−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −17,623−100.0% | Sold out |
| United Capital Financial Advisers, LLC | 0 | $0 | 0.00% | −16,246−100.0% | Sold out |
| M Holdings Securities, Inc. | 0 | $0 | 0.00% | −10,750−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −3,453−100.0% | Sold out |